These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1720156)

  • 1. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction.
    De Conno F; Caraceni A; Zecca E; Spoldi E; Ventafridda V
    J Pain Symptom Manage; 1991 Nov; 6(8):484-6. PubMed ID: 1720156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
    Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
    Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
    Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
    Peng X; Wang P; Li S; Zhang G; Hu S
    World J Surg Oncol; 2015 Feb; 13():50. PubMed ID: 25889313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.
    Barcia E; Martín A; Azuara ML; Sánchez Y; Negro S
    Support Care Cancer; 2007 Jan; 15(1):57-62. PubMed ID: 16847606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of inoperable gastrointestinal obstruction in terminal cancer patients.
    Ventafridda V; Ripamonti C; Caraceni A; Spoldi E; Messina L; De Conno F
    Tumori; 1990 Aug; 76(4):389-93. PubMed ID: 1697993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.
    Ripamonti C; Mercadante S; Groff L; Zecca E; De Conno F; Casuccio A
    J Pain Symptom Manage; 2000 Jan; 19(1):23-34. PubMed ID: 10687323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of malignant bowel obstruction.
    Ripamonti CI; Easson AM; Gerdes H
    Eur J Cancer; 2008 May; 44(8):1105-15. PubMed ID: 18359221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
    Barcia E; Reyes R; Luz Azuara M; Sánchez Y; Negro S
    Support Care Cancer; 2003 Feb; 11(2):107-13. PubMed ID: 12560939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
    Mercadante S
    J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
    [No Abstract]   [Full Text] [Related]  

  • 11. Colonic distention at CT colonography: randomized evaluation of both IV hyoscine butylbromide and automated carbon dioxide insufflation.
    Nagata K; Fujiwara M; Shimamoto T; Iida N; Mogi T; Mitsushima T
    AJR Am J Roentgenol; 2015 Jan; 204(1):76-82. PubMed ID: 25539240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
    Watari H; Hosaka M; Wakui Y; Nomura E; Hareyama H; Tanuma F; Hattori R; Azuma M; Kato H; Takeda N; Ariga S; Sakuragi N
    Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative management of malignant bowel obstruction.
    Ripamonti C; Bruera E
    Int J Gynecol Cancer; 2002; 12(2):135-43. PubMed ID: 11975672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction.
    Mercadante S; Spoldi E; Caraceni A; Maddaloni S; Simonetti MT
    Palliat Med; 1993; 7(4):295-9. PubMed ID: 7505187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyoscine-N-butylbromide by intravenous infusion.
    Butler HE; Moody HR
    Med J Aust; 1987 Sep; 147(6):315-6. PubMed ID: 3626960
    [No Abstract]   [Full Text] [Related]  

  • 16. Some effects of injected hyoscine butylbromide: a versatile class experiment in human pharmacology.
    Herxheimer A; de Groot AC
    Br J Clin Pharmacol; 1977 Jun; 4(3):337-42. PubMed ID: 901701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the value of hyoscine butylbromide and glucagon on aorto iliac intravenous digital subtraction.
    Rowland-Hill CA; Loveday EJ; Thomas ML
    Vasa; 1989; 18(4):301-3. PubMed ID: 2609736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyoscine butylbromide - a review on its parenteral use in acute abdominal spasm and as an aid in abdominal diagnostic and therapeutic procedures.
    Tytgat GN
    Curr Med Res Opin; 2008 Nov; 24(11):3159-73. PubMed ID: 18851775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphine, haloperidol and hyoscine N-butyl bromide combined in s.c. infusion solutions: compatibility and stability. Evaluation in terminal oncology patients.
    Negro S; Reyes R; Azuara ML; Sánchez Y; Barcia E
    Int J Pharm; 2006 Jan; 307(2):278-84. PubMed ID: 16297583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyoscine N-butylbromide does not improve polyp detection during colonoscopy: a double-blind, randomized, placebo-controlled, clinical trial.
    de Brouwer EJ; Arbouw ME; van der Zwet WC; van Herwaarden MA; Ledeboer M; Jansman FG; ter Borg F
    Gastrointest Endosc; 2012 Apr; 75(4):835-40. PubMed ID: 22317882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.